The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era

Ilana Zalcberg Renault, Vanesa Scholl, Rocio Hassan, Paola Capelleti, Marcos de Lima, Jorge Cortes

Research output: Contribution to journalReview article

Abstract

Tyrosine kinase inhibitors have changed the management and outcomes of chronic myeloid leukemia patients. Quantitative polymerase chain reaction is used to monitor molecular responses to tyrosine kinase inhibitors. Molecular monitoring represents the most sensitive tool to judge chronic myeloid leukemia disease course and allows early detection of relapse. Evidence of achieving molecular response is important for several reasons: 1. early molecular response is associated with major molecular response rates at 18-24 months; 2. patients achieving major molecular response are less likely to lose their complete cytogenetic response; 3. a durable, stable major molecular response is associated with increased progression-free survival. However, standardization of molecular techniques is still challenging.

Original languageEnglish (US)
Pages (from-to)455-460
Number of pages6
JournalRevista Brasileira de Hematologia e Hemoterapia
Volume33
Issue number6
DOIs
StatePublished - Dec 1 2011
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Cytogenetics
Disease-Free Survival
Recurrence
Polymerase Chain Reaction

Keywords

  • BCR-ABL positive
  • Chronic
  • Cytogenetic
  • Leukemia
  • Monitoring
  • Mutation
  • Myelogenous
  • Polymerase chain reaction

ASJC Scopus subject areas

  • Hematology

Cite this

The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era. / Renault, Ilana Zalcberg; Scholl, Vanesa; Hassan, Rocio; Capelleti, Paola; de Lima, Marcos; Cortes, Jorge.

In: Revista Brasileira de Hematologia e Hemoterapia, Vol. 33, No. 6, 01.12.2011, p. 455-460.

Research output: Contribution to journalReview article

Renault, Ilana Zalcberg ; Scholl, Vanesa ; Hassan, Rocio ; Capelleti, Paola ; de Lima, Marcos ; Cortes, Jorge. / The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era. In: Revista Brasileira de Hematologia e Hemoterapia. 2011 ; Vol. 33, No. 6. pp. 455-460.
@article{d8836c8cdc9240e2adb1d02f82267c3f,
title = "The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era",
abstract = "Tyrosine kinase inhibitors have changed the management and outcomes of chronic myeloid leukemia patients. Quantitative polymerase chain reaction is used to monitor molecular responses to tyrosine kinase inhibitors. Molecular monitoring represents the most sensitive tool to judge chronic myeloid leukemia disease course and allows early detection of relapse. Evidence of achieving molecular response is important for several reasons: 1. early molecular response is associated with major molecular response rates at 18-24 months; 2. patients achieving major molecular response are less likely to lose their complete cytogenetic response; 3. a durable, stable major molecular response is associated with increased progression-free survival. However, standardization of molecular techniques is still challenging.",
keywords = "BCR-ABL positive, Chronic, Cytogenetic, Leukemia, Monitoring, Mutation, Myelogenous, Polymerase chain reaction",
author = "Renault, {Ilana Zalcberg} and Vanesa Scholl and Rocio Hassan and Paola Capelleti and {de Lima}, Marcos and Jorge Cortes",
year = "2011",
month = "12",
day = "1",
doi = "10.5581/1516-8484.20110122",
language = "English (US)",
volume = "33",
pages = "455--460",
journal = "Hematology, Transfusion and Cell Therapy",
issn = "2531-1379",
publisher = "Elsevier Editora Ltda",
number = "6",

}

TY - JOUR

T1 - The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era

AU - Renault, Ilana Zalcberg

AU - Scholl, Vanesa

AU - Hassan, Rocio

AU - Capelleti, Paola

AU - de Lima, Marcos

AU - Cortes, Jorge

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Tyrosine kinase inhibitors have changed the management and outcomes of chronic myeloid leukemia patients. Quantitative polymerase chain reaction is used to monitor molecular responses to tyrosine kinase inhibitors. Molecular monitoring represents the most sensitive tool to judge chronic myeloid leukemia disease course and allows early detection of relapse. Evidence of achieving molecular response is important for several reasons: 1. early molecular response is associated with major molecular response rates at 18-24 months; 2. patients achieving major molecular response are less likely to lose their complete cytogenetic response; 3. a durable, stable major molecular response is associated with increased progression-free survival. However, standardization of molecular techniques is still challenging.

AB - Tyrosine kinase inhibitors have changed the management and outcomes of chronic myeloid leukemia patients. Quantitative polymerase chain reaction is used to monitor molecular responses to tyrosine kinase inhibitors. Molecular monitoring represents the most sensitive tool to judge chronic myeloid leukemia disease course and allows early detection of relapse. Evidence of achieving molecular response is important for several reasons: 1. early molecular response is associated with major molecular response rates at 18-24 months; 2. patients achieving major molecular response are less likely to lose their complete cytogenetic response; 3. a durable, stable major molecular response is associated with increased progression-free survival. However, standardization of molecular techniques is still challenging.

KW - BCR-ABL positive

KW - Chronic

KW - Cytogenetic

KW - Leukemia

KW - Monitoring

KW - Mutation

KW - Myelogenous

KW - Polymerase chain reaction

UR - http://www.scopus.com/inward/record.url?scp=84856341173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856341173&partnerID=8YFLogxK

U2 - 10.5581/1516-8484.20110122

DO - 10.5581/1516-8484.20110122

M3 - Review article

C2 - 23049363

AN - SCOPUS:84856341173

VL - 33

SP - 455

EP - 460

JO - Hematology, Transfusion and Cell Therapy

JF - Hematology, Transfusion and Cell Therapy

SN - 2531-1379

IS - 6

ER -